Fundz

Slate Medicines Appoints Kenneth Koblan as Chief Scientific Officer

RECENTLY ACQUIREDSep 14, 2026
New to company · from Vesalius Therapeutics“Prior to joining Slate, he served as Head of Research and Development at Vesalius Therapeutics.”

Position

Chief Scientific Officer

Company

Slate Medicines

Kenneth Koblan
RaleighBiotechnologyHealth Care

Description

Slate Medicines Inc. has announced the appointment of Kenneth Koblan, PhD, as Chief Scientific Officer. Dr

Quick answer

Slate Medicines Appoints Kenneth Koblan as Chief Scientific Officer (September 14, 2026). Slate Medicines is based in Raleigh, North Carolina, United States.

Who is the new Chief Scientific Officer at Slate Medicines?
Slate Medicines named Kenneth Koblan Chief Scientific Officer, announced September 14, 2026.
What did Slate Medicines announce on September 14, 2026?
Slate Medicines Inc. has announced the appointment of Kenneth Koblan, PhD, as Chief Scientific Officer.
Where did Kenneth Koblan work before joining Slate Medicines?
Kenneth Koblan joins from Vesalius Therapeutics.
What does Slate Medicines do?
Slate Medicines, Inc. is a biotech company focused on advancing next generation therapeutics for migraine and other headache disorders.
Where is Slate Medicines based?
Slate Medicines is based in Raleigh, North Carolina, United States.

Source: Fundz verified event record.

Who to call at Slate Medicines, and when

A new leader at Slate Medicines brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Slate Medicines raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Slate Medicines, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Slate Medicines. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Slate Medicines

Location

Raleigh, North Carolina, United States

About

Slate Medicines, Inc. is a biotech company focused on advancing next generation therapeutics for migraine and other headache disorders. The Company’s lead program, SLTE-1009, is a potential best-in-class subcutaneous anti-PACAP for the prevention of migraine and other headache disorders. It aims to provide new options for patients underserved by current treatments. Slate Medicines is backed by leading healthcare investors, including RA Capital Management, Forbion, and Foresite Capital.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Slate Medicines changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Slate Medicines's next move

Learn about Strategic plan

Slate Medicines changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.